Intracavitary administration of OK-432 with subcutaneous priming for malignant ascites in a case of advanced renal cell carcinoma

Int J Urol. 2002 Jan;9(1):57-9. doi: 10.1046/j.1442-2042.2002.00411.x.

Abstract

The intracavitary injection of OK-432 (a streptococcal preparation) with subcutaneous priming has been shown to be an effective immunotherapy for patients with malignant effusion. We applied this treatment in a case of advanced renal cell carcinoma with massive ascites. The patient received 0.2 Klinishe Einheit (KE) OK-432 in the subcutaneous injection twice (day 1 and day 7) followed by 10KE OK-432 intra-abdominal administration (day 9). The treatment was performed safely without major side-effects except for transient pyrexia. A significant reduction of ascites was noted 1 month after the treatment without subsequent re-accumulation. Intracavitary injection of OK-432 with subcutaneous priming seems to be a simple, safe and effective treatment for ascites in advanced renal cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Ascites / drug therapy*
  • Ascites / etiology
  • Carcinoma, Renal Cell / complications
  • Carcinoma, Renal Cell / drug therapy*
  • Disease Progression
  • Humans
  • Injections
  • Kidney Neoplasms / complications
  • Kidney Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Picibanil / administration & dosage*

Substances

  • Antineoplastic Agents
  • Picibanil